Evidence Hub

Antimicrobial susceptibility profile of multidrug-resistant uropathogens in community-acquired urinary tract infections in Spain: A multicenter GEIAP-SEIMC study

Riquelme-Bravo E, Molina-Cano M, Domínguez-Jiménez MC, Poliakova-Mazneva Y, March-Roselló GA, Lorenzo-Vidal B, Benítez-Merelo MÁ, GEIAP Study Group of the SEIMC

Enfermedades infecciosas y microbiologia clinica (English ed.), 2026

Abstract

Introduction: Urinary tract infections are one of the leading causes of antibiotic prescribing in Primary Care and they generate a high volume of urine cultures in Microbiology laboratories. The empirical management of these infections has been complicated by the increase in antimicrobial resistance.

Objective: To evaluate the antimicrobial susceptibility profiles of extended-spectrum β-lactamase (ESBL) and/or carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolated from urine samples of patients attending Primary Care in Spain during 2022.

Methods: A descriptive, retrospective, multicenter study including urine samples obtained in Primary Care and processed in 43 Spanish laboratories. Data were collected through a structured survey developed by the Primary Care Infection Study Group and distributed via the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC).

Results: Escherichia coli and Klebsiella pneumoniae were the predominant uropathogens and they accounted for 8.4% and 10.3% respectively. The most frequent carbapenemase was OXA-48. Both ESBL-producing E. coli and K. pneumoniae showed high susceptibility to carbapenémicos and aminoglycosides, whereas ciprofloxacin and cotrimoxazole showed low activity. Susceptibility of ESBL-producing E. coli to fosfomycin and nitrofurantoin was 85.8% and 95.6%, respectively. Pseudomonas aeruginosa accounted for 1.7% of isolates, showing high susceptibility to antipseudomonal agents except for…

How strong is the evidence?

Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free